GlassScriptPhysician profile
M David Jackson
NPI 1730177296
$1,463.34
in general payments reported to CMS, 2019-2025
22 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $109 · 2021: $135 · 2022: $161 · 2023: $168 · 2024: $294 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $287.43 | 2022-2025 | |
| Amgen INC. | $162.79 | 2019-2022 | |
| Allergan, INC. | $161.29 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $153.13 | 2023-2025 | Xeomin |
| Ani Pharmaceuticals, INC. | $101.00 | 2025 | Purified Cortrophin Gel |
| Bioventus LLC | $95.40 | 2019-2024 | Durolane |
| Scilex Pharmaceuticals INC. | $80.80 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $79.88 | 2019-2021 | |
| Pfizer INC. | $54.69 | 2019-2020 | |
| Averitas Pharma INC. | $50.83 | 2023 | Qutenza |
| Pacira Therapeutics, INC. | $32.32 | 2019 | |
| Grt US Holding, INC. | $29.91 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $26.69 | 2022 | |
| Ferring Pharmaceuticals INC. | $25.30 | 2020-2024 | Adstiladrin |
| Medtronic, INC. | $19.66 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $18.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2020 | |
| Tonix Medicines, INC. | $15.44 | 2025 | Tonmya |
| Boston Scientific Corporation | $14.60 | 2022 | |
| Ibsa Pharma INC. | $14.18 | 2024 | Licart, Tirosint |
| Orthogenrx INC. | $13.22 | 2019 | |
| Daiichi Sankyo INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.